

Hearing Date and Time: May 26, 2021, at 9:00 a.m. (prevailing Eastern Time)
Objection Date and Time: April 23, 2021, at 4:00 p.m. (prevailing Eastern Time)

DAVIS POLK & WARDWELL LLP
450 Lexington Avenue
New York, New York 10017
Telephone: (212) 450-4000
Facsimile: (212) 701-5800
Marshall S. Huebner
Benjamin S. Kaminetzky
Timothy Graulich
Eli J. Vonnegut
Darren S. Klein
Christopher S. Robertson

*Counsel to the Debtors
and Debtors in Possession*

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

**PURDUE PHARMA L.P., et al.,

Debtors.¹**

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**NOTICE OF CONVERSION OF MAY 20, 2021 DISCLOSURE STATEMENT HEARING
TO STATUS CONFERENCE AND ADJOURNMENT OF DISCLOSURE
STATEMENT HEARING TO MAY 26, 2021**

PLEASE TAKE NOTICE that on March 15, 2021, Purdue Pharma L.P. and its affiliated debtors and debtors in possession (collectively, the “**Debtors**”) filed (i) the *Joint Chapter 11 Plan*

¹ The Debtors in these cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors’ corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

of *Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors* (as may be modified, amended, or supplemented from time to time, the “**Plan**”) and (ii) the *Disclosure Statement for Chapter 11 Plan for Purdue Pharma L.P. and Its Affiliated Debtors* (as modified, amended, or supplemented from time to time, the “**Disclosure Statement**”).²

PLEASE TAKE FURTHER NOTICE that the hearing on the *Debtors’ Motion to Approve (I) the Adequacy of Information in the Disclosure Statement, (II) Solicitation and Voting Procedures, (III) Forms of Ballots, Notices and Notice Procedures in Connection Therewith, and (IV) Certain Dates with Respect Thereto* (the “**Motion**”) seeking entry of an order approving, among other things, (a) the adequacy of information in the Disclosure Statement, (b) Solicitation and Voting Procedures, (c) forms of Ballots, notices and notice procedures in connection therewith and (d) certain dates with respect thereto was scheduled for May 20, 2021, at 10:00 a.m. (prevailing Eastern Time) (the “**Disclosure Statement Hearing**”).

PLEASE TAKE FURTHER NOTICE that the Disclosure Statement Hearing on May 20, 2021, at 10:00 a.m. (prevailing Eastern Time) has been converted to a status conference (the “**Status Conference**”).

At the Status Conference, the Debtors will provide an update to the Court on the resolution of certain objections to the Disclosure Statement and the material progress that has been made on finalizing the terms of the Disclosure Statement and the Plan.

PLEASE TAKE FURTHER NOTICE that the Disclosure Statement Hearing has been adjourned to **May 26, 2021, at 9:00 a.m. (prevailing Eastern Time)** before the Honorable Robert D. Drain, United States Bankruptcy Judge, United States Bankruptcy Court for the Southern District of New York, 300 Quarropas Street, White Plains, New York 10601 (the “**Bankruptcy**”).

² Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Plan or Disclosure Statement, as applicable. The Debtors reserve the right to amend, supplement, or modify the Plan or the Disclosure Statement.

Court”); *provided* that, pursuant to General Order M-543, dated March 20, 2020 (Morris, C.J.) (“**General Order M-543**”), the Disclosure Statement Hearing shall be conducted telephonically so long as General Order M-543 is in effect or unless otherwise ordered by the Bankruptcy Court.³ The Disclosure Statement Hearing may be continued from time to time by the Court or the Debtors **without further notice** other than by such adjournment being announced in open court, by Agenda Filed with the Court, and/or by a Notice of Adjournment Filed with the Court and served on all parties entitled to notice.

PLEASE TAKE FURTHER NOTICE that the deadline for filing objections (“**Objections**”) to the Disclosure Statement and the Motion was **April 23, 2021, at 4:00 p.m. (prevailing Eastern Time)** (the “**Objection Deadline**”). The deadline for (i) any party that timely filed an Objection to file a supplemental objection to the Disclosure Statement and the Motion and (ii) any party with respect to whom the Objection Deadline remained pending as of the date hereof on account of an extension granted by the Debtors to file an Objection was **May 3, 2021, at 4:00 p.m. (prevailing Eastern Time)**. Absent an extension granted by the Debtors, any objection that has not yet been filed is untimely.

PLEASE TAKE FURTHER NOTICE that the deadline for filing replies to any objections to the Disclosure Statement or the Motion has been extended to **May 24, 2021 at 12:00 p.m. (prevailing Eastern Time)**.

PLEASE TAKE FURTHER NOTICE that the Disclosure Statement (including the Plan and the other exhibits thereto), the Motion or related documents, may be obtained at no charge from Prime Clerk LLC, the Solicitation Agent retained by the Debtors in these chapter 11 cases (the “**Solicitation Agent**”), by (a) calling the Debtors’ restructuring hotline at (844) 217-0912

³ A copy of General Order M-543 can be obtained by visiting <http://www.nysb.uscourts.gov/news/court-operations-under-exigent-circumstances-created-covid-19>.

(toll-free) or (347) 859-8093 (international); (b) visiting the Debtors' restructuring website at <https://restructuring.primeclerk.com/purduepharma>; (c) writing to Purdue Pharma Ballot Processing, c/o Prime Clerk LLC, One Grand Central Place, 60 East 42nd Street, Suite 1440, New York, New York 10165; and/or (d) emailing purduepharmainfo@primeclerk.com. You may also obtain copies of any pleadings filed in these chapter 11 cases for a fee via PACER at <http://www.nysb.uscourts.gov>.

Dated: May 19, 2021
New York, New York

DAVIS POLK & WARDWELL LLP

By: /s/ Darren S. Klein

450 Lexington Avenue
New York, New York 10017
Telephone: (212) 450-4000
Facsimile: (212) 701-5800
Marshall S. Huebner
Benjamin S. Kaminetzky
Timothy Graulich
Eli J. Vonnegut
Darren S. Klein
Christopher S. Robertson

*Counsel to the Debtors
and Debtors in Possession*